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Untreated, fetal mortality is at least 90%, for each fetus (5). Treatment by fetoscopic 12 laser coagulation (FLC) is effective with survival of two babies approaching 60% (6). FLC 13 also reduces the risk of neurodevelopmental morbidity compared to other treatments (7).
14 Improvement in recipient cardiac function is noted within 48 hours of FLC in approximately 15 half of recipients (8), which is associated with improved fetal outcome (9).
16
Metabolomics is the holistic untargeted study of metabolism (10) and investigates the 17 final downstream product of genotype-environment interactions. It provides the identification 18 of a dynamic and sensitive phenotypic signature associated with human health ageing and 19 disease molecular pathophysiology (10). In human pregnancy, this technique has been 20 used to investigate intrauterine growth restriction (IUGR) (11-14), pre-eclampsia (15-17) 21 and gestational diabetes (18, 19) . In non-pregnant adults, it has been used to profile 22 functional and metabolic changes associated with heart failure (20, 21). prospectively staged using the Quintero system (28).
43

Cardiac function assessment
44
High-resolution fetal ultrasound and echocardiography were performed in the recipient with 45 curvilinear array transducers (7-3.5 MHz) on a Siemens S3000 ultrasound machine 
Fetoscopic laser coagulation (FLC)
55
FLC was performed using local anaesthesia (1% lignocaine skin/myometrial infiltration) and 56 maternal Remifentanil sedation as previously described (30). A selective sequential FLC 57 technique was used, with an additional "Solomon" procedure in some cases (31). No 58 amnio-infusion was performed.
59
Non-targeted UHPLC-MS metabolomics analysis
60
All solvents and chemicals applied were of HPLC analytical grade (J.T. Baker, U.K.).
61
Sample collection and preparation. A 10ml sample of amniotic fluid was taken at 62 insertion of the fetoscope into the recipient amniotic sac and then a further 10ml sample 63 withdrawn at the end of the laser coagulation treatment. The median duration of the laser 64 procedure and amniodrainage the median duration was 34 (range 21 -45) minutes.
65
Samples were stored at -80°C before preparation and analysis. All samples were 66 randomised to ensure no correlation between order of preparation and subject, disease 67 grade or date of sample collection. Deproteinisation was performed as described below. Amniotic fluid extracts for each subject were analysed in a random order; the two samples 96 for each subject were analysed sequentially. energy production appears to change following treatment to be preferential for fatty acids.
193
The balance between carbohydrate and fatty acid metabolism appears to be related to 
207
In adults with cardiac failure, prediction of survival is optimal when cardiac ultrasound 208 measurements are combined with serum-derived biomarkers (41). Classically, the 209 combination of cardiac Troponin T, atrial natriuretic polypeptide (ANP) and BNP is used as 210 a marker to reflect cardiac dysfunction and a combination is better than one peptide alone.
211
In recent years there has been a move to a metabolomic approach for profiling functional 212 and metabolic changes in adults with heart failure (21). Contributors: WBD and JWA analysed samples, interpreted data and wrote manuscript.
284
TVM helped with calculation of the MPI and normalising these data as gestationally related 
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